Clinical Edge Journal Scan

Overtreatment does not benefit older patients with early ER+ breast cancer


 

Key clinical point: High rates of sentinel lymph node biopsy (SLNB) and radiotherapy (RT) do not show benefit in older women with early estrogen receptor-positive (ER+) breast cancer.

Major finding: Among all patients, 65.3% received SLNB and 54.4% received adjuvant RT. No association was found between SLNB and locoregional recurrence-free survival (LRFS; P = .71) or disease-free survival (DFS; P = .11). RT showed no association with LRFS ( P = .10) or DFS ( P = .97).

Study details: A retrospective cohort study of 3,361 consecutive patients aged 70 years or older with early ER+ breast cancer.

Disclosures: This study was funded by UPMC Health Services Division and Shear Family Foundation. The authors declared receiving consulting fees, personal fees and/or research funding outside this work.

Source: Carleton N et al. JAMA Netw Open. 2021 Apr 1. doi: 10.1001/jamanetworkopen.2021.6322.

Recommended Reading

Personalized cancer vaccine shows early promise across tumor types
Breast Cancer ICYMI
Quicker fertility rebound in young women with breast cancer
Breast Cancer ICYMI
Cell-free DNA improves response prediction in breast cancer
Breast Cancer ICYMI
FDA panel backs atezolizumab for mTNBC – at least for now
Breast Cancer ICYMI
AHA statement flags CV risk of hormonal cancer therapies
Breast Cancer ICYMI
TNBC: Sacituzumab govitecan extends survival
Breast Cancer ICYMI
Breast cancer: IOERT boost noninferior to EBRT in terms of local control
Breast Cancer ICYMI
Pembrolizumab plus eribulin shows activity in HR+, HER2-negative breast cancer
Breast Cancer ICYMI
Breast cancer: Detrimental effects of adjuvant chemotherapy on QoL in older patients subside after 3 years
Breast Cancer ICYMI
Metastatic breast cancer: Add-on alisertib shows survival benefit
Breast Cancer ICYMI